Our Woundcare Offerings

By PuraMed Supplies

Who Can Benefit from Offering Placenta-Derived Membranes?

• Podiatrists & Wound Care Specialists treating DFUs and chronic wounds. • Hospitals & Outpatient Clinics looking to enhance wound care services. • Distributors & Medical Supply Chains seeking innovative, high-demand products.

Placenta-Derived Membranes for Diabetic Foot Ulcers: A Comprehensive Guide for Healthcare Providers

  • Introduction
  • Diabetic foot ulcers (DFUs) present a significant challenge in patient care, with high morbidity and mortality rates highlighting the need for advanced treatment options. Placenta-derived membranes have emerged as a promising solution, offering unique benefits for chronic wound management. This guide explores the clinical and economic considerations of using placental products for DFU treatment.

  • Clinical Efficacy of Placenta-Derived Membranes
  • Superior Healing Rates
  • • Meta-analysis shows 6.25 times higher odds of complete ulcer healing compared to standard care.
  • • Faster wound closure and shorter healing times observed in multiple studies.
  • Mechanism of Action
  • Placental membranes promote healing through:
  • • Multipotent mesenchymal stem cells that enhance tissue regeneration.
  • • Release of regenerative growth factors such as EGF, TGF-β, VEGF, and PDGF.
  • • Anti-inflammatory and immunomodulatory properties that reduce infection risks.

  • Reduced Infection Risk & Amputation Rates
  • • Placenta-derived membranes contain natural growth factors and anti-inflammatory properties that enhance wound repair.
  • • Evidence suggests lower infection rates and a reduced risk of lower limb amputations.

  • Comparisons with Alternative Treatments
  • Treatment Type Healing Rate Infection Reduction Cost Efficiency
  • Standard Wound Care Slow Moderate High
  • Skin Substitutes Moderate Moderate-High Moderate
  • Placenta-Derived Membranes Fast High Cost-Effective
  • Key Attributes of Placenta-Derived Membranes
  • Biocompatibility & Ease of Use
  • • Non-immunogenic properties make PDMs suitable for various patient profiles.
  • • Easy application in outpatient settings with minimal training required.

  • Versatility in Clinical Use
  • • Suitable for chronic and acute wounds, including deep and complex ulcers.
  • • Can be used in combination with other wound therapies.

Differentiating Between Placenta-Derived Membrane Solutions

Source and Processing Methods• Tissue Source: Amnion, chorion, or both.• Processing Techniques: • Cryopreserved: Maintains cell viability. • Dehydrated: Offers longer shelf life and easier storage. Growth Factor Composition & Bioactivity• Products vary in growth factor concentration, impacting healing rates and effectiveness.• Some membranes include additional extracellular matrix components to support tissue regeneration. Application Method & Handling• Pre-hydrated vs. Dry Formats: Hydrated membranes may be easier to apply, while dry formats offer extended shelf life.• Ease of Integration: Some solutions are designed for single-use applications, while others require multiple layers or specific handling techniques. Clinical Evidence & Regulatory Approvals• Evaluate products with peer-reviewed clinical studies demonstrating efficacy.• Consider FDA-clearance and reimbursement classifications for optimal integration into clinical practice. Cost & Reimbursement Considerations• Compare unit cost vs. healing time savings to determine the best value.• Identify products covered by insurance and Medicare reimbursements to maximize financial feasibility. Improved Reimbursement & Profitability• Falls within existing reimbursement frameworks (Medicare, private insurance, etc.).• Increased practice revenue through higher patient throughput and efficiency. Clinical ConsiderationsPatient Selection• Ideal for chronic DFUs unresponsive to conventional therapies.• Consider patient factors such as diabetes control and vascular status. Research Highlights• 92% of wounds treated with dehydrated human amnion/chorion membrane (dHACM) achieved complete closure within 6 weeks.• Viable cryopreserved placental membrane (vCPM) demonstrated significant improvements in wound healing outcomes.• Placenta-derived mesenchymal stem cells hydrogel showed promising results in a case study, with complete healing after 3 weeks of topical treatment.

Get in touch

We’d love to hear from you! Whether you have a question, need assistance, or just want to share your thoughts, our team is ready to help. Visit our Contact page to reach out, and we'll get back to you as soon as possible.

Subscribe to our newsletter

Sign up with your email address to receive news and updates.